As Target150 has been telling us for a while now, Stem Cells have great benefits in treating Covid-19. A patent has been granted by the Ministry of Economy for the development of an innovative and promising treatment for COVID-19 infections using stem cells.
As Target150 has been telling us for a while now, Stem Cells have great benefits in treating Covid-19. A patent has been granted by the Ministry of Economy for the development of an innovative and promising treatment for COVID-19 infections using stem cells.
Fasting is a deeply spiritual experience sanctioned by the Islamic faith, but medical experts also point out neurological and nutritional benefits for the human body and brain. For centuries, Ramadan, the Islamic holy month in which the faithful fasts from sunrise to sunset, brings a lot of joy to Muslims worldwide
HOUSTON, April 29, 2020 /PRNewswire/ -- Marker Therapeutics, Inc.(Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that theUnited States Food and Drug Administration(FDA) Office of Orphan Products Development has granted Orphan Drug designation to MT-401, a multi-tumor-associated antigen (MultiTAA)-specific T cell product for the treatment of patients with acute myeloid leukemia (AML), following allogeneic stem cell transplant. "We are pleased that theFDAhas granted orphan designation to MT-401, our novel MultiTAA-specific T cell product candidate and believe it is supportive of its potential to treat post allogeneic stem cell transplant patients with AMLa devastating and pervasive blood disease with a high medical need for a treatment. In investigator-sponsored trials, our MultiTAA-specific T cell product candidate was well-tolerated and we have observed clinical benefit across various liquid and solid tumors, suggesting the product candidate's ability to induce a patient's own T cells to expand for a more durable anti-tumor effect
Fasting is a deeply spiritual experience sanctioned by the Islamic faith, but medical experts also point out neurological and nutritional benefits for the human body and brain. For centuries, Ramadan, the Islamic holy month in which the faithful fasts from sunrise to sunset, brings a lot of joy to Muslims worldwide
RICHMOND For the doctors treating the hundreds of patients who are hospitalized for COVID-19 in Virginia, theres no playbook. The disease that has spread rapidly across the world killing hundreds in the state and more than 200,00 worldwide has no known treatment, so COVID-19 has presented a unique challenge to the doctors faced with saving lives against a mostly-unknown enemy
To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser.Is this happening to you frequently? Please report it on our feedback forum
Moderna Boosts Production with Lonza Deal Moderna Therapeutics (MRNA) announced its new collaboration with Lonza for boosting its production capacity for mRNA 1273. The company had recently struck a deal with the federal government to focus on developing COVID 19 vaccine candidate.
Reviewed by Emily Henderson, B.Sc.May 2 2020 Researchers at the UCLA Jonsson Comprehensive Cancer Center and colleagues have found that adding a drug once commonly used to treat schizophrenia to traditional radiation therapy helped improve overall survival in mice with glioblastoma, one of the deadliest and most difficult-to-treat brain tumors. The findings, published in Proceedings of the National Academy of Sciences, show that a combination of radiation and the drug trifluoperazine not only targets glioblastoma cells but also helps overcome the resistance to treatment so common to this aggressive form of cancer.
Reviewed by Emily Henderson, B.Sc.May 2 2020 Researchers at the UCLA Jonsson Comprehensive Cancer Center and colleagues have found that adding a drug once commonly used to treat schizophrenia to traditional radiation therapy helped improve overall survival in mice with glioblastoma, one of the deadliest and most difficult-to-treat brain tumors. The findings, published in Proceedings of the National Academy of Sciences, show that a combination of radiation and the drug trifluoperazine not only targets glioblastoma cells but also helps overcome the resistance to treatment so common to this aggressive form of cancer. The results could prove promising for patients with the disease, for whom the median survival time is only 12 to 18 months following diagnosis.
Recent Comments